Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

RuiYi signs agreement with Genor BioPharma for development of RYI-008 in China

RuiYi signs agreement with Genor BioPharma for development of RYI-008 in China

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

CMC Biologics, RuiYi to develop a cell line for RYI-008

CMC Biologics, RuiYi to develop a cell line for RYI-008

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

NIAID findings provide structural basis for developing RSV vaccine

NIAID findings provide structural basis for developing RSV vaccine

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere, Daiichi Sankyo sign clinical trial agreement

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Integral Molecular releases MPS antibody discovery platform

Integral Molecular releases MPS antibody discovery platform

New collaboration to expand vaccine approaches for melanoma

New collaboration to expand vaccine approaches for melanoma

DecImmune and DSM to develop proprietary antibody therapeutic

DecImmune and DSM to develop proprietary antibody therapeutic

Edible malarial vaccine may work against other viral and bacterial infections

Edible malarial vaccine may work against other viral and bacterial infections

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.